Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578197 | 0.80 | CA12 (0.36) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL10621031 | 0.74 | CA12 (0.31) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL4432972 | 0.71 | ALDH1A1 (0.40) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL30392964 | 0.69 | KMT2A (0.39) | MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL16767652 | 0.69 | ERN1 (0.33) | CA12CA1CA9ERN1 | |
| SCHEMBL3889315 | 0.67 | ALOX15 (0.44) | CA12CA1CA9ALDH1A1CASP1 | |
| SCHEMBL610788 | 0.66 | CA12 (0.41) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL3837265 | 0.65 | TSHR (0.47) | CA12CA1CA9ALDH1A1 | |
| SCHEMBL20837977 | 0.64 | CA12 (0.42) | CA12CA1CA9KMT2AALDH1A1 | |
| SCHEMBL265065 | 0.64 | CA1 (0.40) | CA12CA1CA9ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195556-B2 | Reversible protein multimers, methods for their production and use | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20180346606-A1 | REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-12-06 | — | — | US | disclosed |
| US-10023657-B2 | Reversible protein multimers, methods for their production and use | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20130289253-A1 | REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012044999-A2 | REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346606-A1 | REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE | CD4, CD74, CD69 | CA12 1443/4885CA1 706/4885CA9 2507/4885 |
| US-12195556-B2 | Reversible protein multimers, methods for their production and use | CD4, CD74, MICA | CA12 3405/4885CA1 2616/4885CA9 4254/4885 |
| US-20130289253-A1 | REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USE | CD4, CD74, CD69 | CA12 1443/4885CA1 706/4885CA9 2507/4885 |
| US-10023657-B2 | Reversible protein multimers, methods for their production and use | CD4, CD74, CD69 | CA12 1443/4885CA1 706/4885CA9 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.